Iluvien (fluocinolone acetonide)

No dosing information is available for this tab.

No dosing information is available for this tab.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

• Fungal infection of eye
• Fungal keratitis
• Herpes simplex keratitis
• Herpes simplex keratoconjunctivitis
• Herpes zoster keratitis
• Herpes zoster keratoconjunctivitis
• Ocular infection
• Tuberculosis of the eye
• Vaccinia virus keratitis

• Glaucoma
• Ocular hypertension

• Cataracts

There is no enhanced messaging for this drug.

More Frequent

• Blurred vision
• Cataracts
• Ocular hypertension
• Ocular infection
• Reduced visual acuity
• Vitreous hemorrhage

Less Frequent

• Anemia
• Choroidal detachment
• Conjunctival hemorrhage
• Glaucoma
• Hypertension
• Pneumonia
• Pruritus of skin
• Retinal hemorrhage
• Vitreous detachment

Rare or Very Rare

• Corneal degeneration
• Endophthalmitis
• Iridocyclitis
• Migration of implant
• Ocular hypotony
• Retinal detachment

More Frequent

• Arthralgia
• Blepharoptosis
• Dry eye
• Eye tearing
• Ocular pain
• Pharyngitis
• Visual field defect
• Vitreous floater

Less Frequent

• Anterior chamber inflammation
• Conjunctival hyperemia
• Conjunctivitis
• Constipation
• Corneal edema
• Cough
• Dizziness
• Fever
• Foreign body sensation of eye
• Headache disorder
• Kidney disease with reduction in glomerular filtration rate (GFr)
• Myopia
• Ocular discharge
• Ocular discomfort
• Ocular inflammation
• Ocular irritation
• Ocular itching
• Optic atrophy
• Photophobia
• Posterior capsule opacification
• Sinusitis
• Upper respiratory infection
• Urinary tract infection
• Visual changes

No enhanced messaging available.

No enhanced messaging available.

Some corticosteroids have been shown to be teratogenic when applied in high dosages to the eyes of pregnant animals. Safety of intensive or protracted use of ophthalmic or otic corticosteroids during pregnancy has not been established. EENT corticosteroids should be used in pregnant women, particularly in large doses or for prolonged periods, only when the possible benefits outweigh the potential risks. Women should be instructed to inform their physicians if they become or wish to become pregnant while receiving glucocorticoids. If intranasal corticosteroids must be used during pregnancy or if the patient becomes pregnant while taking the drug, the possible benefits should be weighed against the potential risks. Infants born to mothers who receive nasal corticosteroids during pregnancy should be carefully monitored for symptoms of adrenal insufficiency, and appropriate therapy should be begun immediately if such symptoms appear.

It is not known whether topically administered corticosteroids are distributed into milk or whether they can suppress growth or cause other adverse effects in nursing infants. Some manufacturers state that women receiving pharmacologic doses of dexamethasone should be advised not to nurse their infants.

No enhanced messaging available.